Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Charlotte L. Smith
Observed names:
Charlotte Smith,
Smith, Charlotte
Institutions:
Hôpital Necker-Enfants Malades,
Centre National de la Recherche Scientifique,
Inserm,
Université Paris Cité,
Institut Necker Enfants Malades,
Assistance Publique – Hôpitaux de Paris,
Laboratoire d'hématologie,
University of Birmingham
show all 8
Observed institutions:
Hôpital Necker-Enfants Malades,
Centre National de la Recherche Scientifique,
Inserm,
Université Paris Cité,
Institut Necker Enfants Malades,
Assistance Publique – Hôpitaux de Paris,
Université Paris Descartes,
Laboratoire d'hématologie,
University of Birmingham
show all 9
ORCID:
0000-0002-7209-9287
Observed ORCID:
0000-0002-7209-9287
OpenAlex ID:
A5069499304
Blueprint of human thymopoiesis reveals molecular mechanisms of stage-specific TCR enhancer activation
2020
·
Agata Cieslak
, Guillaume Charbonnier
, et al.
·
The Journal of Experimental Medicine
·
69
PDF
BET protein targeting suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response
2019
·
Guillaume P. Andrieu
, Jordan S. Shafran
, et al.
·
Cancer Letters
·
69
Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup
2021
·
Aurore Touzart
, Anand Mayakonda
, et al.
·
Science Translational Medicine
·
47
PDF
Epigenetic Silencing Affects l -Asparaginase Sensitivity and Predicts Outcome in T-ALL
2019
·
Aurore Touzart
, Etienne Lengliné
, et al.
·
Clinical Cancer Research
·
45
IL7-receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK-inhibition
2023
·
Lucien Courtois
, Aurelie Cabannes-Hamy
, et al.
·
Blood
·
44
PDF
PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL
2021
·
Guillaume P. Andrieu
, Milena Kohn
, et al.
·
Blood
·
43
PDF
Dynamics of broad H3K4me3 domains uncover an epigenetic switch between cell identity and cancer-related genes
2021
·
Mohamed Belhocine
, Mathieu Simonin
, et al.
·
Genome Research
·
38
PDF
TAL1 activation in T-cell acute lymphoblastic leukemia: a novel oncogenic 3’ neo-enhancer
2023
·
Charlotte Smith
, Ashish Goyal
, et al.
·
Haematologica
·
31
PDF
Harnessing the MYB-dependent TAL1 5’super-enhancer for targeted therapy in T-ALL
2023
·
Charlotte Smith
, Aurore Touzart
, et al.
·
Molecular Cancer
·
21
PDF
Low level CpG island promoter methylation predicts a poor outcome in adult T-cell acute lymphoblastic leukemia
2019
·
Aurore Touzart
, Nicolas Boissel
, et al.
·
Haematologica
·
19
PDF
PHF6 -altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
2023
·
Antoine Pinton
, Lucien Courtois
, et al.
·
Clinical Cancer Research
·
15
PDF
DNA methylation as a new tool for the differential diagnosis between T‐ LBL and lymphocyte‐rich thymoma
2024
·
Mehdi Latiri
, Mohamed Belhocine
, et al.
·
The Journal of Pathology
·
8
PDF
Surface pTα expression predicts LCK activation and preclinical synergy of LCK and JAK coinhibition in adult T-ALL
2025
·
Lucien Courtois
, Antoine Pinton
, et al.
·
Blood
·
7
TREC mediated oncogenesis in human immature T lymphoid malignancies preferentially involves ZFP36L2
2023
·
Estelle Balducci
, Thomas Steimlé
, et al.
·
Molecular Cancer
·
7
PDF
Oncogenomic profiling in infant–toddler T‐ALL identifies NKX2 family genes as drivers linked to favorable outcomes
2025
·
Manon Delafoy
, Estelle Balducci
, et al.
·
HemaSphere
·
5
PDF
Towards methylation-based redefinition of TAL1 positive T-cell acute lymphoblastic leukaemia (T-ALL)
2025
·
Charlotte Smith
, Guillaume Charbonnier
, et al.
·
Leukemia
·
2
Neo‐enhancers in T‐cell acute lymphoblastic Leukaemia (T‐ ALL ) and beyond
2025
·
Charlotte Smith
, Vahid Asnafi
, et al.
·
International Journal of Cancer
·
2
TLX1 translocation variants and enhancer hijacking influence clinical outcome in T‐cell acute lymphoblastic leukemia
2025
·
Estelle Balducci
, Thomas Steimlé
, et al.
·
HemaSphere
·
1
PDF
Supplementary Figure S2 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
2024
·
Antoine Pinton
, Lucien Courtois
, et al.
PDF
Supplementary Table S1 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
2024
·
Antoine Pinton
, Lucien Courtois
, et al.
Data from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
2024
·
Antoine Pinton
, Lucien Courtois
, et al.
Supplementary Table S2 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
2024
·
Antoine Pinton
, Lucien Courtois
, et al.
Supplementary Figure S1 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
2024
·
Antoine Pinton
, Lucien Courtois
, et al.
Supplementary Table S3 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
2024
·
Antoine Pinton
, Lucien Courtois
, et al.
Supplementary Table S3 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
2024
·
Antoine Pinton
, Lucien Courtois
, et al.
Show more works
View as search
Works count:
41
Citation count:
473
H-index:
11
I10-index:
11
Year
Topic
Type